X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their IND application to evaluate DK210 (EGFR).
Lead Product(s): DK210,Paclitaxel,Carboplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: MPM BioImpact
Deal Size: $41.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 28, 2023
Details:
DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules. The combination of two cytokines increases potency and reduces toxicity while targeting system also improves the drug's efficacy, safety, and manufacturability.
Lead Product(s): DK210,Paclitaxel,Oxaliplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2023
Details:
DK210 (EGFR) is the first of several experimental therapeutics developed as part of Deka’s platform of molecules. The combination of two cytokines increases potency and reduces toxicity while targeting system also improves the drug's efficacy, safety, and manufacturability.
Lead Product(s): DK210,Paclitaxel,Oxaliplatin
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
DK210 is a promising new cancer treatment that combines normal interleukin-2 with a high affinity interleukin-10, that is designed to accumulate in tumors by binding to the epidermal growth factor receptor.
Lead Product(s): DK210
Therapeutic Area: Oncology Product Name: DK210
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
